8-K: Rocket Pharmaceuticals Receives Complete Response Letter from FDA for KRESLADI Gene Therapy

The FDA issued a Complete Response Letter to Rocket Pharmaceuticals for its KRESLADI gene therapy, requesting additional manufacturing information.

Summary

• Rocket Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for KRESLADI, a gene therapy for severe leukocyte adhesion deficiency-I (LAD-I).
• The FDA is requesting additional Chemistry Manufacturing and Controls (CMC) information to complete its review.
• Rocket Pharmaceuticals met with FDA senior leaders to align on the scope of the required additional CMC information.
• The company is working to provide the requested information to support the approval of KRESLADI as quickly as possible.
• Clinical data from a Phase 1/2 study showed 100% overall survival at 12 months post-infusion for all nine LAD-I patients, with follow-up ranging from 18 to 42 months.
• The study also demonstrated significant reductions in infections and resolution of skin lesions, with no treatment-related serious adverse events.

Sentiment

Score: 5

Explanation: The document contains both positive clinical data and a negative regulatory setback. The positive clinical data is encouraging, but the CRL and need for additional CMC information temper the overall sentiment.

Positives

• The FDA is working closely with Rocket Pharmaceuticals to expedite the approval process.
• Clinical data shows 100% overall survival at 12 months post-infusion for all nine LAD-I patients.
• The therapy demonstrated significant reductions in infections and resolution of skin lesions.
• KRESLADI was well tolerated with no treatment-related serious adverse events.
• The company has received multiple designations for KRESLADI, including RMAT, Rare Pediatric, and Fast Track in the U.S., and PRIME and ATMP in the EU.

Negatives

• The FDA issued a Complete Response Letter (CRL), indicating that the application is not yet approved.
• The FDA has requested additional Chemistry Manufacturing and Controls (CMC) information, which will require further work and time.

Risks

• The need for additional CMC information could delay the approval of KRESLADI.
• There is no guarantee that the FDA will approve KRESLADI even after the additional information is provided.
• The company is dependent on third parties for development, manufacturing, marketing, sales and distribution of product candidates.
• The company faces competition from other companies developing treatments for similar conditions.

Future Outlook

Rocket Pharmaceuticals is working to provide the requested CMC information to the FDA to support the approval of KRESLADI as quickly as possible. The company is also continuing to advance its pipeline of genetic therapies for rare disorders.

Management Comments

• It is reassuring to have the FDA as a close collaborator who understands the high unmet medical need, clear clinical benefit and importance of timely patient access, said Gaurav Shah, M.D., Chief Executive Officer, Rocket Pharma.
• CBER leaderships direct involvement and commitment to working expeditiously to deliver this therapy to patients gives us great hope on behalf of the primary immunodeficiency community.

Industry Context

The announcement highlights the challenges and regulatory hurdles in bringing gene therapies to market, particularly for rare diseases. The FDA's request for additional CMC information is not uncommon and reflects the agency's focus on ensuring the quality and consistency of manufacturing processes for these complex therapies. This is a common issue for companies in the gene therapy space.

Comparison to Industry Standards

• The 100% overall survival rate in the Phase 1/2 study is a positive result, especially when compared to the natural history of LAD-I, where survival beyond childhood is rare without a successful bone marrow transplant.
• The need for additional CMC information is not unusual in the regulatory process for gene therapies, and many companies have faced similar requests.
• Companies like bluebird bio and uniQure have also experienced regulatory delays and requests for additional information for their gene therapy products.

Stakeholder Impact

• Shareholders may react negatively to the delay in approval.
• Patients with LAD-I and their families may experience disappointment due to the delay in access to the therapy.
• Employees of Rocket Pharmaceuticals will need to focus on addressing the FDA's requests.

Next Steps

• Rocket Pharmaceuticals will provide the requested additional CMC information to the FDA.
• The company will continue to work with the FDA to support the approval of KRESLADI.

Key Dates

Keywords

KRESLADI, gene therapy, LAD-I, FDA, Complete Response Letter, CMC, regulatory, biotechnology, rare disease, clinical trial